3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
687
Breast Neoplasms
585
Neoplasms
468
Colorectal Neoplasms
300
Prostatic Neoplasms
263
Neoplasm Metastasis
257
Melanoma
242
Ovarian Neoplasms
228
Recurrence
216
Lung Neoplasms
203
Multiple Myeloma
196
Lymphoma, Non-Hodgkin
155
Pancreatic Neoplasms
154
Leukemia, Myeloid, Acute
142
Carcinoma, Hepatocellular
141
Stomach Neoplasms
137
Lymphoma
131
Carcinoma, Renal Cell
128
Glioblastoma
118
Squamous Cell Carcinoma of Head and Neck
113
Head and Neck Neoplasms
113
Lymphoma, Follicular
106
Leukemia, Lymphocytic, Chronic, B-Cell
99
Small Cell Lung Carcinoma
96
Lymphoma, Large B-Cell, Diffuse
96
Leukemia
96
Brain Neoplasms
91
Carcinoma
82
Uterine Cervical Neoplasms
77
Triple Negative Breast Neoplasms
73
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
INDUSTRY
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts